Impact of risk factors on the occurrence of arterial thrombosis and venous thromboembolism in adults with primary immune thrombocytopenia – Results from two nationwide cohorts-Reference-Cited by-同舟云学术

Impact of risk factors on the occurrence of arterial thrombosis and venous thromboembolism in adults with primary immune thrombocytopenia – Results from two nationwide cohorts

Published:2019-06 Issue: Volume:178 Page:124-131
ISSN:0049-3848
Container-title:Thrombosis Research
language:en
Short-container-title:Thrombosis Research

Author:

Ekstrand Charlotta^ORCID,Linder Marie,Baricault Bérangère,Lafaurie Margaux,Sailler Laurent,Lapeyre-Mestre Maryse,Kieler Helle,Moulis Guillaume,Bahmanyar Shahram

Funder

Centre for Pharmacoepidemiology

Publisher

Elsevier BV

Subject

Hematology

Reference45 articles.

1. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group;Rodeghiero;Blood,2009

2. The immune thrombocytopenia syndrome: a disorder of diverse pathogenesis and clinical presentation;Cines;Hematol. Oncol. Clin. North Am.,2009

3. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology;George;Blood,1996

4. Newly diagnosed immune thrombocytopenia adults: clinical epidemiology, exposure to treatments, and evolution. Results of the CARMEN multicenter prospective cohort;Moulis;Am. J. Hematol.,2017

5. The association between idiopathic thrombocytopenic purpura and cardiovascular disease: a retrospective cohort study;Chandan;J. Thromb. Haemost.,2018

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The immune thrombocytopenia paradox: Should we be concerned about thrombosis in ITP?;Thrombosis Research;2024-09

2. Post-marketing safety surveillance of fostamatinib: an observational, pharmacovigilance study leveraging FAERS database;Expert Opinion on Drug Safety;2024-08

3. Thrombosis in patients with immune thrombocytopenia: incidence, risk, and clinical outcomes;Research and Practice in Thrombosis and Haemostasis;2024-01

4. Risk‐based and individualised management of bleeding and thrombotic events in adults with primary immune thrombocytopenia (ITP);European Journal of Haematology;2023-12-13

5. Risk of thrombotic events in immune thrombocytopenia patients treated with thrombopoietic agents: a systematic review and meta-analysis;Thrombosis Journal;2023-06-23